Drug Profile
Orteronel - Takeda
Alternative Names: TAK-700Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Takeda
- Developer Millennium; Swiss Group for Clinical Cancer Research; Takeda; Takeda Oncology
- Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Naphthalenes; Pyrrolidines; Small molecules
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 25 Jan 2024 Efficacy data from a phase III trial in Prostate cancer presented at the Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 02 Jun 2023 Biomarker analysis data from a phase III SWOG-S1216 trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 04 Jun 2021 Efficacy and safety data from a phase III trial in Prostate cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)